Trevi TherapeuticsTRVI
TRVI
About: Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Employees: 31
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
700% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 8 (+7) [Q1 2025]
381% more call options, than puts
Call options by funds: $10.7M | Put options by funds: $2.23M
200% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 14
68% more capital invested
Capital invested by funds: $330M [Q4 2024] → $554M (+$225M) [Q1 2025]
66% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 32
25% more funds holding
Funds holding: 110 [Q4 2024] → 137 (+27) [Q1 2025]
2.2% more ownership
Funds ownership: 88.95% [Q4 2024] → 91.16% (+2.2%) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12.50
105%
upside
Avg. target
$19.70
223%
upside
High target
$24
294%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert | 245%upside $21 | Buy Maintained | 2 Jun 2025 |
HC Wainwright & Co. Brandon Folkes | 245%upside $21 | Buy Initiated | 28 May 2025 |
Needham Serge Belanger | 294%upside $24 | Buy Reiterated | 20 May 2025 |
B. Riley Securities Mayank Mamtani | 228%upside $20 | Buy Reiterated | 19 Mar 2025 |
HC Wainwright & Co. Oren Livnat | 105%upside $12.50 | Buy Reiterated | 19 Mar 2025 |
Financial journalist opinion
Based on 8 articles about TRVI published over the past 30 days
Neutral
PRNewsWire
1 week ago
Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
NEW HAVEN, Conn. , June 5, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced the closing of its previously announced underwritten public offering of 20,010,000 shares of its common stock at a public offering price of $5.75 per share, which includes 2,610,000 additional shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the public offering at the public offering price, less underwriting discounts and commissions.
Neutral
PRNewsWire
1 week ago
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
NEW HAVEN, Conn. , June 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced the pricing of its previously announced underwritten public offering of 17,400,000 shares of its common stock at a public offering price of $5.75 per share, for total proceeds of $100 million, before deducting underwriting discounts and commissions and expenses payable by Trevi.
Neutral
PRNewsWire
1 week ago
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
NEW HAVEN, Conn. , June 2, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock.
Positive
Benzinga
1 week ago
Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients
Trevi Therapeutics, Inc. TRVI revealed topline results on Monday from its Phase 2b CORAL trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) (N=165).
Neutral
PRNewsWire
1 week ago
Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p
Neutral
PRNewsWire
1 week ago
Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn.
Neutral
PRNewsWire
2 weeks ago
Trevi Therapeutics to Participate in Upcoming June Conferences
NEW HAVEN, Conn. , May 29, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in June.
Neutral
PRNewsWire
3 weeks ago
Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
Results of analyses presented at an investor meeting during the American Thoracic Society 2025 International Conference NEW HAVEN, Conn. , May 20, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced additional analyses from the Phase 2a RIVER trial of Haduvio for the treatment of patients with RCC (N=66).
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?
The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 195.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
Seeking Alpha
1 month ago
Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Jennifer Good - Co-Founder, President and Chief Executive Officer Lisa Delfini - Chief Financial Officer James Cassella - Chief Development Officer Farrell Simon - Chief Commercial Officer Conference Call Participants Faisal Khurshid - Leerink Annabel Samimy - Stifel Leland Gershell - Oppenheimer Deepa Njama - Jones Trading Mayank Mamtani - B. Riley Securities Kaveri Pohlman - Clear Street Operator Good afternoon and welcome to the Trevi Therapeutics First Quarter 2025 Earnings Conference Call.
Charts implemented using Lightweight Charts™